

**Date: 13.11.2019**

**To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai - 400 001**


**Sub: Submission of Un-Audited Standalone Financials Results of the Company and Limited Review Report as per Provisions of Regulation 30, 33 of SEBI (LODR) Regulations, 2015.**


Please find enclosed here with the following Documents in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015:

1. Financial Results: Un-Audited Standalone Financial Results of the company for the Second Quarter/Half Year Ended 30<sup>th</sup> September, 2019.
2. Limited Review Report: A Certified Copy of the Limited Review Report on Standalone Financials for the Second Quarter/Half Year Ended 30<sup>th</sup> September, 2019 by the Auditors.

This is for your Information and Necessary Records.

Thanking you  
For **TRIMURTHI LIMITED**

  
**Arun Kumar Bhangadia**  
Managing Director  
DIN: 00021024



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956

Date: 13.11.2019

To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai- 400 001

Sub: Outcome of the Board Meeting held on 13/11/2019 as per Regulation 30, 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

The Board of Directors of the Company at its meeting held today, Wednesday, the 13<sup>th</sup> Day of November, 2019 at Registered Office, have approved and taken on record the following:


1. The Board has considered and approved the minutes of the previous board meeting.
2. The Board has considered and approved the Unaudited Standalone Financial Results for the Second Quarter/Half Year ended 30<sup>th</sup> September, 2019 along with Limited Review Report issued by the Statutory Auditors of the Company in compliance with Indian Accounting Standards (Ind-AS), SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013.

There being no other matter meeting of the Board of Directors concluded with the vote of thanks.

The Meeting of the Board of Directors of the company commenced at 03.30 P.M. and Concluded at 04:30 P.M.

Request you to take same on records.

Thanking you  
For TRIMURTHI LIMITED

  
Arun Kumar Bhangadia  
Managing Director  
DIN: 00021024



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





**TRIMURTHI**  
GROUP

TRIMURTHI LIMITED  
4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095.  
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS  
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 2019

Rs. in lakhs except share data

PARTICULARS	QUARTER ENDED			HALF YEARLY ENDED	
	30.09.2019 (UNAUDITED)	30.06.2019 (UNAUDITED)	30.09.2018 (UNAUDITED)	30.09.2019 (UNAUDITED)	30.09.2018 (UNAUDITED)
<b>1. INCOME</b>					
INCOME FROM OPERATIONS	14.73	19.12	107.03	33.86	211.47
OTHER INCOME	8.26	16.74	1.54	25.00	2.41
<b>TOTAL INCOME</b>	<b>23.00</b>	<b>35.86</b>	<b>108.58</b>	<b>58.86</b>	<b>213.88</b>
<b>2. EXPENSES</b>					
PURCHASES	18.37	17.10	85.11	35.47	160.75
COST OF MATERIALS CONSUMED	-	-	-	-	-
MANUFACTURING EXPENSES	-	-	-	-	-
WORK IN PROGRESS AND STOCK IN TRADE	1.52	(1.86)	-	(0.33)	7.16
RENT	0.60	-	0.60	0.60	1.25
EMPLOYEE BENEFITS EXPENSE	7.35	5.49	8.48	12.84	14.70
FINANCE COSTS	-	-	-	-	-
DEPRECIATION AND AMORTISATION EXPENSES	1.97	2.67	2.99	4.64	6.01
OTHER EXPENSES	4.55	8.67	7.78	13.22	19.52
<b>TOTAL EXPENSES</b>	<b>34.36</b>	<b>32.08</b>	<b>104.96</b>	<b>66.43</b>	<b>209.39</b>
<b>3. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE EXCEPTIONAL ITEMS (1-2)</b>	<b>(11.36)</b>	<b>3.78</b>	<b>3.62</b>	<b>(7.58)</b>	<b>4.49</b>
<b>4. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS</b>					
<b>5. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (3-4)</b>	<b>(11.36)</b>	<b>3.78</b>	<b>3.62</b>	<b>(7.58)</b>	<b>4.49</b>
<b>6. TAX EXPENSES</b>					
-CURRENT TAX	(1.02)	1.07	(2.20)	0.05	(4.70)
-TAX ADJUSTMENTS RELATING TO EARLIER YEARS	(1.10)	1.10	0.29	-	-
-DEFERRED TAX (NET)	0.08	(0.02)	(1.91)	0.05	(4.70)
<b>7. NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (5-6)</b>	<b>(10.34)</b>	<b>2.71</b>	<b>5.82</b>	<b>(7.63)</b>	<b>9.19</b>
<b>8. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS</b>					
<b>9. TAX EXPENSES FOR DISCONTINUED OPERATIONS</b>					
<b>10. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-9)</b>					
<b>11. PROFIT/(LOSS) FOR THE PERIOD (7+10)</b>	<b>(10.34)</b>	<b>2.71</b>	<b>5.82</b>	<b>(7.63)</b>	<b>9.19</b>
<b>12. OTHER COMPREHENSIVE INCOME</b>					
A. (i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS					
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS					
B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	0.67	(1.90)	(3.25)	(1.23)	(7.82)
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS					
<b>13. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT (LOSS) AND OTHER COMPREHENSIVE INCOME)</b>	<b>(9.67)</b>	<b>0.81</b>	<b>2.57</b>	<b>(8.86)</b>	<b>1.37</b>
<b>14. EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION) :</b>					
(i) BASIC	(0.13)	0.03	0.07	(0.09)	0.11
(ii) DILUTED	(0.13)	0.03	0.07	(0.09)	0.11
<b>15. EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION) :</b>					
(i) BASIC					
(ii) DILUTED					
<b>16. EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION) :</b>					
(i) BASIC	(0.13)	0.03	0.07	(0.09)	0.11
(ii) DILUTED	(0.13)	0.03	0.07	(0.09)	0.11

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





PARTICULARS	QUARTER ENDED			HALF YEARLY ENDED	
	30.09.2019 (UNAUDITED)	30.06.2019 (UNAUDITED)	30.09.2018 (UNAUDITED)	30.09.2019 (UNAUDITED)	30.09.2018 (UNAUDITED)
<b>PARTICULARS OF SHARE HOLDING</b>					
Public Share Holding					
- Number of Shares	29,00,600	29,00,600	29,00,600	29,00,600	29,00,600
- Percentage of shareholding	35.18%	35.81%	35.18%	35.81%	35.81%
Promoters and promoter group shareholding					
a. Pledged / encumbered					
- No of Equity Shares	-	-	-	-	-
- Percentage of Shares (of the shareholding of promoter and promoter group)	-	-	-	-	-
- Percentage of Shares (of the total share capital of the company)	-	-	-	-	-
b. Non encumbered					
- No of Equity Shares	51,99,400	51,99,400	51,99,400	51,99,400	51,99,400
- Percentage of Shares (of the shareholding of promoter and promoter group)	64.19%	64.19%	64.19%	64.19%	64.19%
- Percentage of Shares (of the total share capital of the company)	100.00%	100.00%	100.00%	100.00%	100.00%

Particulars	3 Months Ended ( 30/09/2019)
<b>Investor Complaints</b>	
Pending at the beginning of the quarter	
Received during the quarter	-
Disposed during the quarter	-
Remaining unsolved during the quarter	-

PARTICULARS	QUARTER ENDED			HALF YEARLY ENDED	
	30.09.2019 (UNAUDITED)	30.06.2019 (UNAUDITED)	30.09.2018 (UNAUDITED)	30.09.2019 (UNAUDITED)	30.09.2018 (UNAUDITED)
<b>Segment Revenue</b>					
a. Pharma Business	-	-	-	-	-
b. Financial Services	-	-	-	-	-
c. Investments	8.21	12.88	13.83	21.09	30.81
d. Trading in Shares	0.06	3.85	2.08	3.91	2.08
e. Foods	14.73	19.12	6.00	33.86	17.27
	-	-	86.67	-	163.72
	23.00	35.86	108.58	58.86	213.88
	-	-	-	-	-
<b>Segment Profits ( Before tax &amp; Interest From Each Segment)</b>	23.00	35.86	108.58	58.86	213.88
a. Pharma Business	-	-	-	-	-
b. Financial Services	-	-	-	-	-
c. Investments	15.05	6.18	11.19	21.09	24.83
d. Trading in Shares	0.06	3.85	2.08	3.91	2.08
e. Foods	(26.11)	(6.25)	4.94	(32.58)	6.72
	-	-	(14.60)	-	(29.15)
	(11.00)	3.78	3.62	(7.58)	4.49
i. Interest	-	-	-	-	-
ii. Other Un-allocable expenses net off	-	-	-	-	-
iii. Un-allocable Income	-	-	-	-	-
	-	-	-	-	-
<b>Capital Employed</b>	(11.00)	3.78	3.62	(7.58)	4.49
a. Pharma Business	-	-	-	-	-
b. Financial Services	-	-	-	-	-
c. Investments	546.22	551.39	(9.66)	546.22	522.18
d. Trading in Shares	259.88	260.74	(40.81)	259.88	272.01
e. Foods	373.75	377.29	41.76	373.75	357.30
	12.34	12.45	12.33	12.34	32.11
<b>Total</b>	1,192.18	1,201.86	3.63	1,192.18	1,183.61

Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.

The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 13th November, 2019.

The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.

Place : Hyderabad

Date: 13th November 2019

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956

For Trimurthi Ltd

Arun Kumar Bhangadia





**TRIMURTHI LIMITED**  
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095.




**BALANCE SHEET AS AT 30-09-2019**

(Rs. In Lakhs except EPS)

PARTICULARS		Note Number	Figures as at 30-09-2019		Figures as at 31-03-2019	
<b>ASSETS:</b>						
<b>A. Non Current Assets</b>						
(a)	Property, Plant and Equipment	2.1	32.81		36.86	
(b)	Capital Work In Progress				-	
(c)	Investment Property				-	
(d)	Other Intangible Assets	2.1	0.22		0.37	
<b>(e) Financial Assets</b>						
(i)	Investments	2.2	259.88		272.16	
(ii)	Trade Receivables				-	
(iii)	Loans				-	
(iv)	Other Financial Assets				-	
(f)	Deferred Tax Assets (Net)				-	
(g)	Other Non Current Assets	2.4	20.75		20.75	
				313.66		330.14
<b>B. Current Assets</b>						
(a)	Inventories	2.5	10.60		10.27	
<b>(b) Financial Assets</b>						
(i)	Investments				-	
(ii)	Trade Receivables	2.6	192.58		213.97	
(iii)	Cash & Cash Equivalents	2.7	148.94		16.03	
(iv)	Bank Balances other than (iii) above				-	
(v)	Loans	2.8	390.79		434.46	
(vi)	Others (to be specified)	2.9	132.17		208.25	
				875.09		882.98
<b>TOTAL ASSETS</b>				1,188.75		1,213.12
<b>EQUITY AND LIABILITIES:</b>						
<b>A. Equity</b>						
(a)	Equity Share Capital	2.10	810.00		810.00	
(b)	Other Equity		382.18		391.04	
				1,192.18		1,201.04
<b>B. Non Current Liabilities</b>						
<b>(a) Financial Liabilities</b>						
(i)	Borrowings				-	
(ii)	Trade Payables				-	
(iii)	Other Financial Liabilities				-	
<b>(b) Provisions</b>						
(c)	Deferred Tax Liabilities (Net)	2.11	(6.32)		(6.38)	
(d)	Other Non Current Liabilities			(6.32)	-	(6.38)
<b>B. Current Liabilities</b>						
<b>(a) Financial Liabilities</b>						
(i)	Borrowings				-	
(ii)	Trade Payables	2.12	-		10.38	
(iii)	Other Financial Liabilities				-	
<b>(b) Other Current Liabilities</b>						
(c)	Provisions	2.13	2.89		3.59	
(d)	Current Tax Liabilities (Net)	2.14	-		4.49	
				2.89		18.45
<b>TOTAL EQUITY AND LIABILITIES</b>				1,188.75		1,213.12
Significant Accounting Policies and Notes to Accounts			1 & 2	(0.00)		(0.00)

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956



**TRIMURTHI LIMITED**

(Formerly Known as TRIMURTHI DRUGS &amp; PHARMACEUTICALS LIMITED)

4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad-500095.

**TRIMURTHI**  
GROUP**STANDALONE CASH FLOW STATEMENT FOR THE PERIOD ENDED 30th SEPTMEBER, 2019**

(Rs. In Lakhs)

Particulars	As at 30.09.2019	As at 31.03.2019
<b>A. Cash Flow from Operating Activities:</b>		
Net Profit before Tax and Extraordinary Items	(7.58)	19.08
Adjustments for:		
Depreciation	4.64	12.15
Interest & Other Income	(19.58)	(0.24)
Profit/Loss on Sale of Investments/Car	(3.78)	(12.99)
Other Comprehensive Income	(1.23)	(6.20)
Operating profit before Working Capital Changes	(27.53)	11.80
Adjustments for:		
Trade and Other receivables	141.14	(31.35)
Inventories	(0.33)	0.85
Trade payables	(11.08)	(24.61)
Provision for Tax	(4.49)	3.40
Cash generated from Operations	125.24	(51.72)
Cash flow before Extraordinary Items	97.70	(39.92)
Tax Paid		(4.49)
<b>Net Cash used for Operating activities</b>	<b>97.70</b>	<b>(44.40)</b>
<b>B. Cash Flow from Investing Activities:</b>		
Purchase of Fixed Assets	(0.44)	(6.21)
Sale of Fixed Assets	-	29.25
Capital Work in progress	-	-Nil-
Purchase of Investments	-	21.69
Sale of Investments	16.06	0.15
Increase / (Decrease) in Deposits	-	0.24
Interest & Other Income	19.58	
<b>Net Cash flow from Investing activities</b>	<b>35.20</b>	<b>45.12</b>
<b>C. Cash Flow from Financing Activities:</b>		
Increase in Share Capital	-	-
Increase in Share Premium	-	-
Increase / Decrease in Long Term Borrowings	-	-
Share Issue and Preliminary Expenses	-	-
Dividends Paid	-	-
<b>Net Cash flow from Financing activities</b>	<b>-</b>	<b>-</b>
<b>Net Increase in Cash and Cash Equivalents</b>	<b>132.91</b>	<b>0.72</b>
Cash and Cash Equivalents as at (Opening Balance)	16.03	15.31
Cash and Cash Equivalents as at (Closing Balance)	<b>148.94</b>	<b>16.03</b>

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs &amp; Pharmaceuticals Ltd.)

4-4-231/1/2/ABC, Inderbagh, Sultanbazar,

Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

Email : info@trimurthidrugs.com

Website : www.trimurthidrugs.com

CIN No : L67120TG1994PLC018956





**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA


Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.p murali.com

**Limited Review Report- Standalone Financial Results**

To  
The Board of Directors,  
Trimurthi Limited,  
Hyderabad.

Limited Review Report for the Quarter and Half year ended 30<sup>th</sup> September 2019

1. We have reviewed the accompanying statement of unaudited standalone financial results of Trimurthi Limited ("the Company") for the quarter ended 30<sup>th</sup> September, 2019 and year to date results for the period 1<sup>st</sup> April 2019 to 30<sup>th</sup> September (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including relevant circulars issued by SEBI from time to time.
2. The preparation of "the Statement" in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India read with circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in their meeting held on 13<sup>th</sup> November 2019. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.






**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.p murali.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.  
Chartered Accountants  
FRN: 007257S



A. Krishna Rao  
Partner  
M.No. 020085  
UDIN: 19020085AAAAQA8471

Place: Hyderabad  
Date: 13-11-2019




**TRIMURTHI LIMITED**  
SCHEDULE III OF THE COMPANIES ACT 2013  
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEP, 2019  
PART-I



	Particulars	QUARTER ENDED			HALF YEARLY ENDED	
		30.09.2019 (UNAUDITED)	30.06.2019 (UNAUDITED)	30.09.2018 (UNAUDITED)	30.09.2019 (UNAUDITED)	30.09.2018 (UNAUDITED)
I.	Income From Operations					
	Net Sales / Income from Operations	262.26	243.68	204.86	505.94	540.87
	Other Income	20.18	4.24	1.73	24.43	2.79
II.	Total Income	282.44	247.92	206.59	530.37	543.66
III.	Expenses					
	a. Consumption of Raw Material	35.59	31.47	44.18	67.06	85.69
	b. Purchase of Traded Goods/Shares	154.42	137.91	67.23	292.33	293.66
	c. (Increase)/Decrease in stock in trade and work in Progress	(0.18)	(9.68)	6.40	(9.85)	1.16
	d. Manufacturing Expenses	64.39	39.22	41.94	103.62	77.99
	e. Employee benefits expense	26.24	22.24	21.81	48.48	45.85
	f. Rent	1.50	1.50	1.80	3.00	3.65
	g. Finance Cost	2.67	3.70	3.71	6.37	6.68
	h. Depreciation	4.73	5.33	5.22	10.06	10.35
	i. Other Expenditure	10.78	14.59	12.75	25.36	30.74
	Total	300.13	246.30	205.05	546.43	555.77
IV.	Profit/(Loss) before Exceptional and Tax (II-III)	(17.69)	1.63	1.54	(16.06)	(12.11)
V.	Exceptional Items/Prior Period Items	-	-	-	-	-
VI.	Profit/(Loss) before tax (IV-V)	(17.69)	1.63	1.54	(16.06)	(12.11)
VII.	Tax expense:	(0.50)	2.65	2.05	2.15	(0.23)
	(1) Current tax	(0.94)	2.15	3.80	1.21	4.13
	(2) Deferred tax	0.44	0.50	(1.74)	0.94	(4.37)
VIII.	Net Profit/(Loss) for the period from continuing operations (VI-VII)	(17.19)	(1.03)	(0.52)	(18.22)	(11.87)
IX.	Profit/(loss) from discontinued operations	-	-	-	-	-
X.	Tax expenses of discontinued operations	-	-	-	-	-
XI.	Profit/(loss) from Discontinued operations (after tax) (IX-X)	-	-	-	-	-
XII.	Profit/(loss) for the period (VIII+XI)	(17.19)	(1.03)	(0.52)	(18.22)	(11.87)
XIII.	Other Comprehensive Income					
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	0.67	(1.90)	(3.27)	(1.23)	(7.88)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XIV.	Total Comprehensive Income for the period (XII+XIII) Comprising Profit (Loss) and Other comprehensive Income for the period )	(16.52)	(2.93)	(3.79)	(19.45)	(19.75)
XV.	Minority Interest	0.10	1.12	2.83	1.22	4.79
XVI.	Total Comprehensive Income for the period after Minority Interest (XIV-XV)	(16.63)	(4.05)	(6.62)	(20.67)	(24.54)
XVII.	Earnings per equity share (for continuing operation):					
	(1) Basic	(0.21)	(0.03)	(0.04)	(0.24)	(0.21)
	(2) Diluted	(0.21)	(0.03)	(0.04)	(0.24)	(0.21)
XVIII.	Earnings per equity share (for discontinuing operation):					
	(1) Basic	-	-	-	-	-
	(2) Diluted	-	-	-	-	-
XIX.	Earnings per equity share (for discontinuing & continuing operation):					
	(1) Basic	(0.21)	(0.03)	(0.04)	(0.24)	(0.21)
	(2) Diluted	(0.21)	(0.03)	(0.04)	(0.24)	(0.21)

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





**TRIMURTHI LIMITED**  
SCHEDULE III OF THE COMPANIES ACT 2013  
PART-II



	Particulars	QUARTER ENDED			HALF YEARLY ENDED	
		30.09.2019 (UNAUDITED)	30.06.2019 (UNAUDITED)	30.09.2018 (UNAUDITED)	30.09.2019 (UNAUDITED)	30.09.2018 (UNAUDITED)
<b>A.</b>	<b>Particulars Of Share Holding</b>					
1.	Public Share Holding					
	- Number of Shares	29,00,600	29,00,600	29,00,600	29,00,600	29,00,600
	- Percentage of shareholding	35.81%	35.81%	35.81%	35.81%	35.81%
2.	Promoters and promoter group shareholding					
	a. Pledged / encumbered					
	- No of Equity Shares	-	-	-	-	-
	- Percentage of Shares (of the shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of Shares (of the total share capital of the company)	-	-	-	-	-
	b. Non encumbered					
	- No of Equity Shares	51,99,400	51,99,400	51,99,400	51,99,400	51,99,400
	- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of Shares (of the total share capital of the company)	64.19%	64.19%	64.19%	64.19%	64.19%

Particulars	3 Months Ended ( 30/09/2019)
<b>B. Investor Complaints</b>	
Pending at the beginning of the quarter	-NIL-
Received during the quarter	-NIL-
Disposed during the quarter	-NIL-
Remaining unsolved during the quarter	-NIL-

**Segment Reporting**

	Particulars	QUARTER ENDED			HALF YEARLY ENDED	
		30.09.2019 (UNAUDITED)	30.06.2019 (UNAUDITED)	30.09.2018 (UNAUDITED)	30.09.2019 (UNAUDITED)	30.09.2018 (UNAUDITED)
1.	<b>Segment Revenue</b>					
	a. Pharma Business	148.96	130.90	156.12	279.86	663.56
	b. Financial Services	7.39	12.88	16.98	20.27	57.78
	c. Investments	(0.07)	3.85	-	3.78	12.99
	d. Foods	111.09	81.16	77.05	192.25	318.51
	e. Trading in Shares	15.08	19.12	11.27	34.21	30.81
	<b>Total</b>	<b>282.44</b>	<b>247.92</b>	<b>261.43</b>	<b>530.37</b>	<b>1,083.65</b>
	Less: Inter Segment Revenue	-	-	-	-	-
	<b>Net Sales/ Income From Operations</b>	<b>282.44</b>	<b>247.92</b>	<b>261.43</b>	<b>530.37</b>	<b>1,083.65</b>
2.	<b>Segment Profits ( Before tax &amp; Interest From Each Segment)</b>					
	a. Pharma Business	0.39	3.95	5.15	4.34	23.20
	b. Financial Services	14.09	6.18	13.64	20.27	32.62
	c. Investments	(0.07)	3.85	-	3.78	12.99
	d. Foods	(6.12)	(6.10)	(34.21)	(12.22)	(95.19)
	e. Trading in Shares	(25.97)	(6.25)	1.78	(32.23)	13.97
	<b>Total</b>	<b>(17.69)</b>	<b>1.63</b>	<b>(13.65)</b>	<b>(16.06)</b>	<b>(12.40)</b>
	Less:					
	i. Interest	-	-	-	-	-
	ii. Other Un-allocable expenses net off	-	-	-	-	-
	iii. Un-allocable Income	-	-	-	-	-
	<b>Total Profit Before Tax</b>	<b>(17.69)</b>	<b>1.63</b>	<b>(13.65)</b>	<b>(16.06)</b>	<b>(12.40)</b>
3.	<b>Capital Employed</b>					
	a. Pharma Business	84.70	86.01	85.41	84.70	85.41
	b. Financial Services	449.46	456.43	453.22	449.46	453.22
	c. Investments	37.14	37.72	49.14	37.14	49.14
	d. Foods	189.09	192.02	190.67	189.09	190.67
	e. Trading in Shares	311.01	315.84	313.62	311.01	313.62
	<b>Total</b>	<b>1,071.39</b>	<b>1,088.01</b>	<b>1,092.06</b>	<b>1,071.39</b>	<b>1,092.06</b>

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956






Notes:

- 1 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- 2 The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 13th November, 2019.
- 3 The Standalone Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditors in accordance with Indian Accounting Standards (Ind-AS) as notified by Ministry of Corporate Affairs; Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III Division II of Companies Act, 2013. The Limited Review was carried out by Statutory Auditors for the Quarter ended 30th September, 2017. The Ind AS Complaint figures for the Corresponding previous Quarter ended 30th September, 2016 have not been subject to review or audit, however the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- 4 The results are also available on the webiste of the Company

Place : Hyderabad


Date : 13th November,2019.



TRIMURTHI  
GROUP

**TRIMURTHI LIMITED**


(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956



**CONSOLIDATED BALANCE SHEET AS AT 30-09-2019**

(Rs. In Lakhs except EPS)

PARTICULARS		Note Number	Figures as at the end of 30-09-2019		Figures as at the end of 31-03-2019	
<b>ASSETS:</b>						
<b>A. Non Current Assets</b>						
(a)	Property, Plant and Equipment	2.1	184.14		188.66	
(b)	Capital Work In Progress				-	
(c)	Investment Property				-	
(d)	Other Intangible Assets	2.1	2.46		3.09	
<b>(e) Financial Assets</b>						
(i)	Investments	2.2	36.86		49.14	
(ii)	Trade Receivables				-	
(iii)	Loans				-	
(iv)	Other Financial Assets				-	
(f)	Deferred Tax Assets (Net)				-	
(g)	Other Non Current Assets	2.3	20.98		21.06	
				244.44		261.95
<b>B. Current Assets</b>						
(a)	Inventories	2.4	91.31		79.40	
<b>(b) Financial Assets</b>						
(i)	Investments				-	
(ii)	Trade Receivables	2.5	319.71		328.73	
(iii)	Cash & Cash Equivalents	2.6	165.77		19.93	
(iv)	Bank Balances other than (iii) above				-	
(v)	Loans	2.7	380.25		424.23	
(vi)	Others (to be specified)	2.8	153.42		219.78	
				1110.46		1,072.07
<b>TOTAL ASSETS</b>				1,354.90		1,334
<b>EQUITY AND LIABILITIES:</b>						
<b>A. Equity</b>						
(a)	Equity Share Capital	2.9	810.00		810.00	
(b)	Other Equity		261.39		282.06	
				1071.39		1,092.06
<b>B. Non Controlling Interest</b>						
				51.27		50.05
<b>C. Non Current Liabilities</b>						
<b>(a) Financial Liabilities</b>						
(i)	Borrowings	2.10	85.12		93.07	
(ii)	Trade Payables				-	
(iii)	Other Financial Liabilities				-	
<b>(b) Provisions</b>						
(c)	Deferred Tax Liabilities (Net)	2.11	1.17		0.23	
(d)	Other Non Current Liabilities				-	
				86.29		93.29
<b>D. Current Liabilities</b>						
<b>(a) Financial Liabilities</b>						
(i)	Borrowings				-	
(ii)	Trade Payables	2.12	138.61		80.76	
(iii)	Other Financial Liabilities				-	
<b>(b) Other Current Liabilities</b>						
(c)	Provisions	2.13	6.13		7.35	
(d)	Current Tax Liabilities (Net)	2.14	1.21		10.51	
				145.95		98.62
<b>TOTAL EQUITY AND LIABILITIES</b>				1354.90		1,334.02
Significant Accounting Policies and Notes to Accounts		1 & 2		0.00		(0.00)



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





**TRIMURTHI**  
GROUP

**TRIMURTHI LIMITED**

4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad-500095.

**CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2019**

(Rs. In Lakhs)

Particulars	As at 30.09.2019	As at 31.03.2019
<b>A. Cash Flow from Operating Activities:</b>		
Net Profit before Tax and Extraordinary Items	(16.06)	(12.40)
Adjustments for:		
Depreciation	10.06	21.25
Interest & Other Income	(20.64)	(24.74)
Interest & Other Expense	6.37	12.97
Miscellaneous Exp Write off	0.08	0.15
(Profit)/Loss on Sale of Assets	-	(11.14)
(Profit)/Loss on Sale of Investments	(3.78)	(1.85)
Operating profit before Working Capital Changes	(23.97)	(15.75)
Adjustments for:		
Trade and Other receivables	119.36	(37.85)
Inventories	(11.92)	6.88
Trade payables	56.63	(5.89)
Provision for Tax	(9.30)	9.93
Cash generated from Operations	154.77	(26.93)
Cash flow before Extraordinary Items	130.80	(42.68)
Extraordinary Items and Tax	(1.21)	(10.51)
<b>Net Cash used for Operating activities</b>	<b>129.59</b>	<b>(53.19)</b>
<b>B. Cash Flow from Investing Activities:</b>		
Purchase of Fixed Assets	(4.91)	(14.04)
Sale of Fixed Assets	-	29.25
Capital Work in progress	-	0.00
Purchase/Sale of Investments	14.83	15.49
Increase / (Decrease) in Deposits		0.15
Interest & Other Income	14.27	11.77
<b>Net Cash flow from Investing activities</b>	<b>24.19</b>	<b>42.62</b>
<b>C. Cash Flow from Financing Activities:</b>		
Increase in Share Capital		-Nil-
Increase in Share Premium		-Nil-
Increase / Decrease in Long Term Borrowings	(7.94)	(4.67)
Share Issue and Preliminary Expenses		-Nil-
Dividends Paid		-Nil-
Capital Contribution from Minority Interest		-Nil-
<b>Net Cash flow from Financing activities</b>	<b>(7.94)</b>	<b>(4.67)</b>
<b>Net Increase in Cash and Cash Equivalents</b>	<b>145.83</b>	<b>(15.24)</b>
Cash and Cash Equivalents as at (Opening Balance)	19.93	35.17
Cash and Cash Equivalents as at (Closing Balance)	165.77	19.93

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956







**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com


**Limited Review Report – Consolidated Financial Results**

To  
The Board of Directors,  
Trimurthi Limited,  
Hyderabad.

Limited Review Report for the Quarter and Half year ended 30<sup>th</sup> September 2019

1. We have reviewed the accompanying statement of unaudited consolidated financial results ("the statement") of Trimurthi Limited Group comprising Trimurthi Limited ("the Parent") and its subsidiaries (together referred to as 'the Group'), for the quarter ended 30<sup>th</sup> September, 2019 and year to date results for the period 1<sup>st</sup> April 2019 to 30<sup>th</sup> September ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including relevant circulars issued by SEBI from time to time.
2. The preparation of "the Statement" in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in their meeting held on 13<sup>th</sup> November 2019. Our responsibility is to express a conclusion on "the Statement" based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable







**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA



Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

4. The consolidated unaudited results include the results of the following entities:

- (a) Trimurthi Foods Limited
- (b) Trimurthi Pharmaceuticals India Private Limited

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.  
Chartered Accountants  
FRN: 007257S

  
  
A. Krishna Rao  
Partner  
M.No. 020085  
UDIN: 19020085AAAAQB2552

Place: Hyderabad  
Date: 13-11-2019